Konkuk University Medical Center

- Invited Neurophet’s scientific advisor Stephen Salloway , professor of Neurology at Brown Medical School as guest speaker - Shared latest insights on brain image analysis used for prescription of Alzheimer’s disease treatments such as ‘Leqembi’ and ‘Kisunla’ SEOUL, South Korea , Oct. 18, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, hosted Neurophet Symposium with Professor Stephen Salloway , a leading authority for the establishment of Alzheimer’s treatment guidelines in the U.S., to share the latest insights with domestic medical professionals. About 60 medical professionals from the departments of neurology, radiology, psychiatry, and nuclear medicine, related to the practical use of Alzheimer’s disease treatments, from across the country attended the event. This symposium was held at JW Marriott Hotel Seoul with the title “Alzheimer’s Treatment Era with Neurophet.” At the symposium, international medical professionals exchanged the latest opinions on brain image analysis technology related to the prescription and interpretation of Alzheimer’s disease treatments. Stephen Salloway , professor of Neurology at Brown University and Won-Jin Moon, professor of Radiology at Konkuk University Medical Center attended as speakers. Kee-Hyung Park , professor of Neurology at Gachon University Gil Medical Center and Hyun Kook Lim , professor of Psychiatry at The Catholic University of Korea Yeouido St. Mary’s Hospital also attended as chairs. Neurophet recently appointed Professor Stephen Salloway as scientific advisor. He is a professor of Neurology and Psychiatry at the Warren Alpert Medical School of Brown University . He also serves as the Founding Director of Memory and Aging Program at Butler Hospital in the U.S. Professor Salloway is a leading expert in the field of Alzheimer’s disease treatments, providing clinical guidelines for the prescription of anti-amyloid treatments. He is actively involved in research on anti-amyloid treatments, including comparative studies between donanemab and aducanumab. “This symposium was a valuable exchange between Professor Stephen Salloway , who presented the prescribing criteria for Alzheimer’s disease treatments and leading medical professionals in the field of Alzheimer’s treatment in Korea” said Jake Junkil Been, CEO of Neurophet. “Neurophet will continue to strengthen research and development related to Alzheimer’s disease treatment prescriptions, further enhancing its expertise in brain image analysis.” Last July, Neurophet launched ‘Neurophet AQUA AD’, the software for Alzheimer’s disease (AD) treatment prescription and monitoring treatment effects and side effects. This solution is currently preparing for medical device certifications in Korea, the U.S., and Japan . About Neurophet Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain diseases based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Jake Junkil Been, CEO, and Donghyeon Kim, CTO, who developed the next-generation neuro-navigation system. Major products include brain MRI analysis software “Neurophet AQUA”, brain PET image analysis (PET tracer deposition) software “Neurophet SCALE PET”, brain imaging treatment planning software for electric and magnetic brain stimulation “Neurophet tES/TMS LAB”. Neurophet has set its top priority to helping patients suffering from brain diseases. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain’s health and pioneer solutions for brain diseases with AI technology. View original content to download multimedia: SOURCE Neurophet

New AI fall prediction tool gains ground in Singapore Nanyang Polytechnic (NYP) is expanding the trial of its new AI-based fall prediction tool. Co-developed with medical technology company Longway AI Technologies, the AI system was trained via a 3D convolutional neural network, a deep learning model that teaches a computer to process data the way the human brain and nervous system do. Over 200 hours of videos of human activities involving gait were fed on and trained with the system so it could detect signs of unsteady gait and then alert relevant care teams. Since it was built in 2020 at NYP's Centre for Innovation for Electronics and Internet of Things, it has been piloted at Singapore General Hospital and St. Luke's ElderCare Rivervale Centre. A new trial is ongoing at the SASCO Senior Citizens' Home while another pilot is slated at St. Andrew's Nursing Home. NYP is also in talks with geriatric departments across the country to expand the application of its technology. Konkuk University Hospital, Neurophet tie up for AI-driven Alzheimer's research Konkuk University Hospital and AI medical imaging company Neurophet have signed a research collaboration agreement to further enhance AI-based imaging for Alzheimer's disease diagnosis. Neurophet has developed AI-powered solutions – Neurophet AQUA and Neurophet SCALE PET – that automatically analyse PET and MRI scans to detect biomarkers of Alzheimer's, including amyloid beta and tau proteins. It is currently developing a new solution for total Alzheimer's disease diagnosis , which includes the monitoring of amyloid-related imaging abnormalities. Researchers from Konkuk University Hospital's Department of Radiology who are focused on Alzheimer's research are expected to contribute to Neurophet's ongoing R&D efforts, leveraging the university hospitals' data. Latest remote patient monitoring integrations at India's Apollo Hospitals Apollo Hospitals in Seshadripuram and Bannerghatta Road, both in Bangalore, have introduced remote patient monitoring inside and beyond their facilities. The Seshadripuram branch recently partnered with LifeSigns to install its 24/7 wireless RPM system which leverages AI and wearable biosensors to continuously track vital signs such as ECG, blood pressure, and SPO2, whether in the hospital or at home. Meanwhile, the Bannerghatta Road branch has introduced HealthNet Global's connected ambulance. Powered by 5G connectivity, it provides a live visual feed through onboard cameras and bodycams for paramedics and enables real-time monitoring of vital signs using telemetry devices and patient monitoring applications. The connected ambulance is touted to enhance communications, collaboration, and decision-making of medical teams.

QuantaMatrix’s direct Rapid Antimicrobial Susceptibility Testing system (dRAST™) improves optimal prescription of antibiotics by two days compared to conventional methods This follows successful adoption of dRAST solution in routine clinical use in five clinical laboratories in Europe and Asia Paris, France and Seoul, South Korea, October 5, 2022 - QuantaMatrix, an in vitro diagnostics company specializing in the discovery, development and commercialization of fully integrated solutions within the sepsis value chain, today announces that its dRAST™ solution has been adopted for routine clinical use by admed, a Swiss-based laboratory. This successful implementation is the result of a partnership between QuantaMatrix Europe, a fully owned affiliate of QuantaMatrix Inc., based in Paris (France) and Axonlab, one of the leading in vitro diagnostics solution providers in Europe. This is the sixth application of the dRAST solution, adding to a list of current users that includes Seoul National University Hospital, Chungnam National University Hospital, the Catholic University of Korea Seoul St. Mary’s Hospital, Konkuk University Medical Center and the Limbach Group. admed was created from the merger of three laboratories in the canton of Neuchâtel, Switzerland. As a recognized laboratory based at seven sites, it covers many areas of expertise, such as laboratory medicine, immunopathology and microbiology. Each year, the admed laboratory manages over 3,000 patients with suspected clinical sepsis. admed is committed to the patient’s well-being; providing quick, reliable and qualitative results. These values align well with QuantaMatrix’s mission and the dRAST solution, which has now been adopted at the admed laboratory in routine clinical use. “The implementation of dRAST in our laboratory will greatly simplify our management of positive blood cultures, at all times, while significantly reducing the time required to deliver antibiotic susceptibility test results,” said Dr. Antony Croxatto, director of the microbiology department at the admed laboratory. “Indeed, dRAST will enable us to provide same-day results if the blood cultures are positive and save 16 to 24 hours compared to conventional methods. Patients will more swiftly benefit from appropriate antibiotic therapy, potentially reducing the risks of complications and prolonged hospital stays. dRAST is perfectly in line with our objectives to improve our services for patients and clinicians.” “We are happy to announce this partnership with admed, a company with a wealth of experience and values that align with our own,” said Sunghoon Kwon, CEO of QuantaMatrix. “This is a great opportunity for QuantaMatrix to bring faster diagnoses to patients and create better sepsis care.” QuantaMatrix’s dRAST aims to help clinicians by providing optimal antibiotic treatments for sepsis patients. Its gram-negative and gram-positive antibiotic panels deliver fast results for a large variety of sepsis-causing bacteria. Sepsis is the body’s extreme response to a bacterial infection in the bloodstream. When this occurs, septic shock triggers a chain reaction through the body that leads to tissue damage, organ failure and, if left untreated, death. Globally, today, sepsis claims a life every 2.8 seconds. Statistically, sepsis is the number one cause of death in hospitals, with a 30-day mortality rate of 20 to 30 percent. The treatment of sepsis is a fight against time. Any delay in treatment reduces the survival rate of a patient by 7-9% per hour. The dRAST solution contains various innovative patents and a collection of over 30 million data points on bacteria growth to cut down diagnostic time from several days to as little as four hours. About QuantaMatrix QuantaMatrix Inc. is an in vitro diagnostics company specializing in the discovery, development and commercialization of fully-integrated solutions within the sepsis value chain. QuantaMatrix has successfully established a distribution network all over Europe. It continues to expand and is now addressing the Middle East and Africa. QuantaMatrix specializes in in vitro diagnostics using microbial diagnostics technology. QuantaMatrix’s flagship product is its dRAST™ solution, a direct Rapid Antimicrobial Susceptibility Testing system, which is capable of finding the optimal antibiotic in four to six hours following a positive blood culture. The dRAST solution uses various patented technologies related to optics, microfluidic engineering and artificial intelligence. Compared to conventional methods, dRAST effectively shortens the time to results by two to three days. The dRAST solution is available in Korea, Europe and the Middle East. QuantaMatrix has a distribution network spanning 26 countries in the EMEA region and continues to expand. QuantaMatrix is a public company listed on the Korean KOSDAQ market under #317690.